5-Azacitidine in patients with IDH1/2-mutant recurrent glioma

被引：20
作者：
Federici, Laetitia [1 ]
Capelle, Laurent [2 ]
Annereau, Maxime [1 ]
Bielle, Franck [3 ]
Willekens, Christophe [4 ,5 ]
Dehais, Caroline [6 ]
Laigle-Donadey, Florence [6 ]
Hoang-Xuan, Khe [6 ]
Delattre, Jean-Yves [6 ]
Idbaih, Ahmed [6 ]
Lemare, Francois [1 ]
de Botton, Stephane [4 ,5 ]
Sanson, Marc [6 ]
Touat, Mehdi [6 ,7 ]
机构：
[1] Paris Saclay Univ, Pharm Clin Serv, Gustave Roussy Canc Campus, Villejuif, France
[2] Univ Hosp Pitie Salpetriere Charles Foix, Dept Neurosurg, Paris, France
[3] Sorbonne Univ, Inst Brain & Spinal Cord, Dept Neurosurg, Univ Hosp Pitie Salpetriere Charles Foix,Neuropat, Paris, France
[4] Univ Paris Saclay, Gustave Roussy, Dept Hematol, F-94805 Villejuif, France
[5] Paris Saclay Univ, INSERM, Unit 1170, Gustave Roussy Canc Campus, Villejuif, France
[6] Sorbonne Univ, Inst Brain & Spinal Cord, Univ Hosp Pitie Salpetriere Charles Foix, Dept Neurosurg,Neurol Serv 2 Mazarin, Paris, France
[7] Harvard Med Sch, Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA
来源：
NEURO-ONCOLOGY | 2020年 / 22卷 / 08期
关键词：
CONVENTIONAL CARE REGIMENS; ACUTE MYELOID-LEUKEMIA; OLDER PATIENTS; IDH1; AZACITIDINE; MUTATIONS;
D O I：
10.1093/neuonc/noaa074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1226 / 1228
页数：3
相关论文
共 10 条
  • [1] Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
    Craddock, Charles F.
    Houlton, Aimee E.
    Quek, Lynn Swun
    Ferguson, Paul
    Gbandi, Emma
    Roberts, Corran
    Metzner, Marlen
    Garcia-Martin, Natalia
    Kennedy, Alison
    Hamblin, Angela
    Raghavan, Manoj
    Nagra, Sandeep
    Dudley, Louise
    Wheatley, Keith
    McMullin, Mary Frances
    Pillai, Srinivas P.
    Kelly, Richard J.
    Siddique, Shamyla
    Dennis, Michael
    Cavenagh, Jamie D.
    Vyas, Paresh
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (21) : 6430 - 6440
  • [2] Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
    DiNardo, Courtney D.
    Patel, Keyur P.
    Garcia-Manero, Guillermo
    Luthra, Rajyalakshmi
    Pierce, Sherry
    Borthakur, Gautam
    Jabbour, Elias
    Kadia, Tapan
    Pemmaraju, Naveen
    Konopleva, Marina
    Faderl, Stefan
    Cortes, Jorge
    Kantarjian, Hagop M.
    Ravandi, Farhad
    [J]. LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1925 - 1929
  • [3] International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
    Dombret, Herve
    Seymour, John F.
    Butrym, Aleksandra
    Wierzbowska, Agnieszka
    Selleslag, Dominik
    Jang, Jun Ho
    Kumar, Rajat
    Cavenagh, James
    Schuh, Andre C.
    Candoni, Anna
    Recher, Christian
    Sandhu, Irwindeep
    Bernal del Castillo, Teresa
    Al-Ali, Haifa Kathrin
    Martinelli, Giovanni
    Falantes, Jose
    Noppeney, Richard
    Stone, Richard M.
    Minden, Mark D.
    McIntyre, Heidi
    Songer, Steve
    Lucy, Lela M.
    Beach, C. L.
    Doehner, Hartmut
    [J]. BLOOD, 2015, 126 (03) : 291 - 299
  • [4] Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
    Emadi, Ashkan
    Faramand, Rawan
    Carter-Cooper, Brandon
    Tolu, Seda
    Ford, Laurie A.
    Lapidus, Rena G.
    Wetzler, Meir
    Wang, Eunice S.
    Etemadi, Arash
    Griffiths, Elizabeth A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) : E77 - E79
  • [5] Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    Gattermann, Norbert
    Germing, Ulrich
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven
    Seymour, John F.
    Dombret, Herve
    Backstrom, Jay
    Zimmerman, Linda
    McKenzie, David
    Beach, C. L.
    Silverman, Lewis R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) : 562 - 569
  • [6] IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
    Mondesir, Johanna
    Willekens, Christophe
    Touat, Mehdi
    de Botton, Stephane
    [J]. JOURNAL OF BLOOD MEDICINE, 2016, 7 : 171 - 180
  • [7] Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
    Sanson, Marc
    Marie, Yannick
    Paris, Sophie
    Idbaih, Ahmed
    Laffaire, Julien
    Ducray, Francois
    El Hallani, Soufiane
    Boisselier, Blandine
    Mokhtari, Karima
    Hoang-Xuan, Khe
    Delattre, Jean-Yves
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4150 - 4154
  • [8] Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan, Sevin
    Fabius, Armida W. M.
    Borodovsky, Alexandra
    Pedraza, Alicia
    Brennan, Cameron
    Huse, Jason
    Viale, Agnes
    Riggins, Gregory J.
    Chan, Timothy A.
    [J]. ONCOTARGET, 2013, 4 (10) : 1729 - 1736
  • [9] IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
    Turcan, Sevin
    Rohle, Daniel
    Goenka, Anuj
    Walsh, Logan A.
    Fang, Fang
    Yilmaz, Emrullah
    Campos, Carl
    Fabius, Armida W. M.
    Lu, Chao
    Ward, Patrick S.
    Thompson, Craig B.
    Kaufman, Andrew
    Guryanova, Olga
    Levine, Ross
    Heguy, Adriana
    Viale, Agnes
    Morris, Luc G. T.
    Huse, Jason T.
    Mellinghoff, Ingo K.
    Chan, Timothy A.
    [J]. NATURE, 2012, 483 (7390) : 479 - U137
  • [10] Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide
    Yamashita, Alex Shimura
    Rosa, Marina da Costa
    Borodovsky, Alexandra
    Festuccia, William T.
    Chan, Timothy
    Riggins, Gregory J.
    [J]. NEURO-ONCOLOGY, 2019, 21 (02) : 189 - 200
1